Neumora Therapeutics Inc.... (NMRA)
Neumora Therapeutics Common Stock Statistics
Share Statistics
Neumora Therapeutics Common Stock has 161.56M shares outstanding. The number of shares has increased by 1.68% in one year.
| Shares Outstanding | 161.56M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.96% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 55.17M |
| Failed to Deliver (FTD) Shares | 34.93K |
| FTD / Avg. Volume | 1.19% |
Short Selling Information
The latest short interest is 10.83M, so 6.71% of the outstanding shares have been sold short.
| Short Interest | 10.83M |
| Short % of Shares Out | 6.71% |
| Short % of Float | 19.57% |
| Short Ratio (days to cover) | 11.14 |
Valuation Ratios
The PE ratio is -11.48 and the forward PE ratio is -7.3.
| PE Ratio | -11.48 |
| Forward PE | -7.3 |
| PS Ratio | 0 |
| Forward PS | 9.4 |
| PB Ratio | 5.77 |
| P/FCF Ratio | -16.57 |
| PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Neumora Therapeutics Inc. Common Stock.
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 19.05, with a Debt / Equity ratio of 0.01.
| Current Ratio | 19.05 |
| Quick Ratio | 19.05 |
| Debt / Equity | 0.01 |
| Total Debt / Capitalization | 1.1 |
| Cash Flow / Debt | -31.21 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.5% and return on capital (ROIC) is -39.72%.
| Return on Equity (ROE) | -0.5% |
| Return on Assets (ROA) | -0.48% |
| Return on Capital (ROIC) | -39.72% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.90M |
| Employee Count | 124 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 268.00K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -87.25% in the last 52 weeks. The beta is 0, so Neumora Therapeutics Common Stock's price volatility has been lower than the market average.
| Beta | 0 |
| 52-Week Price Change | -87.25% |
| 50-Day Moving Average | 7.77 |
| 200-Day Moving Average | 10.51 |
| Relative Strength Index (RSI) | 21.06 |
| Average Volume (20 Days) | 2.93M |
Income Statement
| Revenue | n/a |
| Gross Profit | -668.00K |
| Operating Income | -188.19M |
| Net Income | -235.93M |
| EBITDA | -187.53M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -1.49 |
Balance Sheet
The company has 374.04M in cash and 5.23M in debt, giving a net cash position of 368.81M.
| Cash & Cash Equivalents | 374.04M |
| Total Debt | 5.23M |
| Net Cash | 368.81M |
| Retained Earnings | -703.43M |
| Total Assets | 352.54M |
| Working Capital | 316.87M |
Cash Flow
In the last 12 months, operating cash flow was -163.28M and capital expenditures -117.00K, giving a free cash flow of -163.40M.
| Operating Cash Flow | -163.28M |
| Capital Expenditures | -117.00K |
| Free Cash Flow | -163.40M |
| FCF Per Share | -1.03 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
NMRA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -74.5% |
| FCF Yield | -50.69% |
Analyst Forecast
The average price target for NMRA is $21.5, which is 975% higher than the current price. The consensus rating is "Buy".
| Price Target | $21.5 |
| Price Target Difference | 975% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
Scores
| Altman Z-Score | 1.2 |
| Piotroski F-Score | 1 |